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Oral L-Arginine (and
Other Active Ingredients)
for Ischemic Heart Disease?*
Richard O. Cannon III, MD, FACC
Bethesda, Maryland
The endothelium maintains a nonthrombotic surface for
blood flow, prevents platelet and leukocyte activation and
adhesion, modulates cellular composition of the arterial
wall, and promotes dilator tone of arteries and veins,
homeostatic properties regulated in part by the endothelial
synthesis of nitric oxide (NO). Endothelial release of NO is
reduced or absent in patients with coronary artery disease
(CAD) or its risk factors (1) and may contribute to
myocardial ischemia by limiting appropriate blood flow
during stress (2). Furthermore, reduced NO bioactivity—as
evidenced by abnormal dilator responsiveness to acetylcho-
line, cold pressor testing or shear stress during hyperemia—
has been reported by several groups to indicate increased
risk of serious cardiovascular events in the few years that
follow (3,4). Strategies for increasing endothelial NO syn-
thase activity that may be amenable to pharmacologic
intervention include enhanced transcription of the gene for
this enzyme, stabilization of messenger RNA (mRNA) for
greater enzyme synthesis, provision of cofactors for the
enzyme and administration of the substrate, L-arginine.
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This last approach, in particular, has generated consider-
able interest and controversy in recent years. Normally,
L-arginine is not rate-limiting in the enzymatic conversion
of this semi-essential amino acid to L-citrulline and NO:
the cytosolic concentration of L-arginine within endothelial
cells exceeds by a factor of 1,000 the maximum substrate
utilization rate by NO synthase. However, under specific
conditions, administration of L-arginine might be expected
to enhance NO synthesis. First reported by Vallance et al.
(5) a decade ago, methylated arginines such as asymmetric
dimethylarginine (ADMA), enzymatically generated from
proteins that regulate RNA processing and transcriptional
control, may compete with L-arginine for the active sustrate
binding site on NO synthase. Because ADMA cannot be
converted to NO, NO synthesis could be reduced if suffi-
cient L-arginine were displaced. Elevated levels of ADMA
have been measured in serum samples from patients with
hypercholesterolemia and peripheral arterial disease, possi-
bly a consequence of reduced catabolism by the enzyme
dimethylarginine dimethylaminohydrolase (6–8). The rel-
evance of endogenous NO synthase inhibitors to human
atherosclerosis was suggested by a strong association be-
tween ADMA levels and carotid artery intimal-medial
thickness measured by ultrasound in a Japanese population
(9). Additional proposed mechanisms by which L-arginine
bioavailability may be reduced include excess enzymatic
conversion to ornithine via enhanced activity of arginase in
plasma or within endothelial cells (10), and inhibition of
L-arginine transport into endothelial cells (11).
Several groups have reported that intravascular infusion
of L-arginine in patients with CAD and hypercholester-
olemic subjects improves coronary and systemic endothelial
function, often evidenced by prevention of constriction or
enhanced dilation in response to intra-arterial acetylcholine
(12–15). Although improved endothelial function in these
studies is consistent with enhanced substrate availability for
NO synthase, other effects of L-arginine may account for
augmented NO synthesis. In this regard, intravenous infu-
sion of L-arginine stimulates the release of insulin, which in
turn activates endothelial NO synthase and promotes NO
release (16). Furthermore, Nagase et al. (17) reported that
L-arginine or D-arginine reacts nonenzymatically with
H2O2—likely present at least transiently in the high-
oxidant environment of the atherosclerotic arterial wall—to
form NO. These mechanisms of arginine-mediated increase
in NO that are independent of L-arginine substrate avail-
ability for NO synthase may explain why intra-brachial
arterial infusion of D-arginine, which is not a substrate for
this enzyme, improved forearm blood flow responses to
acetylcholine to the same degree as L-arginine in patients
with CAD (18). Regardless of the mechanism of L-arginine
effect on endothelial function, two groups reported that
intravenous infusion of L-arginine failed to improve exercise
tolerance or ST segment responses in patients with CAD
(18,19).
It is possible that longer duration of treatment with
L-arginine is required to improve endothelial function
enough that coronary blood flow increases during stress,
preventing myocardial ischemia. Oral administration of
L-arginine has been reported to improve brachial artery
endothelial function in young hypercholesterolemic subjects
and young patients with CAD, and coronary microvascular
endothelial function in patients without angiographically
significant CAD (20–22). Furthermore, studies including
small numbers of patients with CAD reported improved
exercise performance with delayed appearance of ST-
segment depression and maximum ST-depression after
three days of oral L-arginine (6 g daily) compared with
exercise stress testing on placebo (23), and reduced angina
after three months of oral L-arginine (24).
In the current issue of the Journal, Maxwell et al. (25)
provide a new angle to the L-arginine story by testing the
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possible anti-ischemic effects of a “medical food bar” con-
taining not only L-arginine (3.2 g per bar) but also folate,
vitamins (C, E, B6, B12), niacin and soy isoflavones in a
randomized, double-blind, single crossover trial of 36 pa-
tients with CAD maintained on a regimen of conventional
medication. They report that these study participants had
better brachial artery endothelial function (flow-mediated
dilation), greater exercise duration on treadmill testing and
higher scores on quality of life testing when two medical
food bars were taken daily for two weeks than when two
placebo bars were taken daily for two weeks. However, there
were no significant differences between medical food bar
and placebo periods in the ST segment response or onset of
angina during exercise testing after two weeks of treatment,
or in angina frequency or episodes and duration of ischemia
as assessed by ambulatory monitoring during the two weeks
of treatment. Nevertheless, the authors conclude that this
medical food bar might be useful adjunctive therapy in the
management of symptomatic patients with CAD.
This novel approach to managing ischemic heart disease
is likely to be embraced by many patients eager for alterna-
tive or non-drug treatments for their disease, which already
requires many medications, with a mechanism of action that
is intuitively appealing, free of apparent toxicity and possibly
tastes good as well (at 360 calories a day for two bars).
However, the benefit of oral L-arginine to endothelial
function and exercise performance in patients with CAD on
medical management reported by this group is at variance
with the published experience of two other groups that also
used randomized, double-blind protocols. Blum et al. (26)
administered L-arginine to 30 patients with CAD at a
higher daily dosage (9 g) than, and for twice the duration
(one month) of, the Maxwell et al. study (25). Compared
with the placebo treatment period, no effect of L-arginine
could be demonstrated on flow-mediated brachial artery
dilation (as a bioassay for NO release into the arterial wall),
on levels of nitrogen oxides in serum (as an index of NO
released into the bloodstream), or on levels of markers of
inflammation transcriptionally inhibited by NO in experi-
mental preparations. Walker et al. (27) reported recently
that L-arginine, 15 g daily for two weeks, did not reduce
levels of ADMA or 8-epi-prostaglandin F2 (as a measure
of vascular oxidant stress), improve the forearm blood flow
response to intra-brachial acetylcholine infusion or improve
exercise duration in 20 men with CAD and stable angina
differently than in 20 patients randomized to placebo. In
both studies, significant increases in plasma arginine levels
during L-arginine treatment periods were reported. It is
possible that had medical management been discontinued
(including statins, which improve endothelial function) in
these studies, a robust anti-ischemic effect of L-arginine on
endothelial function and inducible ischemia might have
been detected. However, appropriate medical management
was continued, testing the potential of L-arginine as ad-
junctive therapy to further benefit endothelial NO bioactiv-
ity and improve coronary blood flow during stress in
patients who continue to have myocardial ischemia.
The benefit of the medical food bar of Maxwell et al. (25)
to endothelial function, which is in contrast to the negative
findings of studies cited above that used even higher daily
doses of L-arginine, may be due to the ingredients in the bar
other than L-arginine—folic acid, vitamins and micronu-
trients—that might enhance NO synthesis. Thus, folate
regenerates tetrahydrobiopterin, a critical cofactor for NO
synthase, from its inactive oxidized form. Levels of this
cofactor may be reduced in atherosclerosis, possibly by
increased oxidation to dihydrobiopterin, and contribute to
impaired endothelial function. In this regard, in experimen-
tal preparations, endothelial NO synthase generates super-
oxide anions in the absence of tetrahydrobiopterin (28).
Consistent with increased tetrahydrobiopterin generation,
long-term folate administration improves endothelial func-
tion of patients with CAD (29). Administration of vitamin
C also improves endothelial function of patients with CAD
(30), possibly by increasing levels of tetrahydrobiopterin
from its oxidized form (31). Thus, consistent with the
design of the medical food bar, the biological effect of its
component ingredients on endothelial function could be
greater than any given alone.
So, if this medical food bar actually improves endothelial
function, consistent with enhanced NO bioactivity and with
the potential of improving coronary blood flow, why wasn’t
there objective evidence of an anti-ischemic effect? The
authors believe that the medical therapy taken by patients
may have obscured the anti-ischemic benefit of the medical
food bar as assessed by treadmill exercise testing, although
there was no effect of the medical food bar on ambulatory
ischemia or angina frequency during the treatment period.
However, the improved quality of life scores (especially
“bodily pain” and “vitality” for the SF-36, and “treatment
satisfaction” and “disease perception” for the Seattle Angina
Questionnaire) during the medical food bar treatment
period suggests an interesting line of investigation: the
possible central nervous system effects of enhanced NO
from neuronal NO synthase. Clearly, more placebo-
controlled clinical trials will be necessary to resolve the issue
of L-arginine (and other active ingredients) as adjunctive
therapy for ischemic heart disease and the mechanism of
benefit, if real.
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